Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Single-dose (Long-acting Injectable) or Multiple-dose (Oral) Clinical Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

NCT07722728 is registered in ClinicalTrials.gov with Bostal Drug Delivery Co., Ltd as lead sponsor.

NCT NCT07722728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07722728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Single-dose (Long-acting Injectable) or Multiple-dose (Oral) Clinical Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
Lead sponsor
Bostal Drug Delivery Co., Ltd
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2027
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia